Keagan S Casey

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Matthew J. Frigault, G. Lucchini, Jackie Chappell, 2020, The Lancet.

Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories

Matthew J. Frigault, U. Johansson, S. Lugthart, 2021, Cytometry. Part B, Clinical cytometry.

Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial.

Matthew J. Frigault, T. Batchelor, Yi-Bin Chen, 2022, Blood.

Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel.

Matthew J. Frigault, D. Leaf, Shruti Gupta, 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy

Maristela L Onozato, Matthew J. Frigault, P. Cin, 2020, Leukemia.

A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Matthew J. Frigault, N. Horick, R. Shen, 2021, Blood.